Sažetak
Abstract
Background/Aim: Pregabalin, initially developed as an antiepileptic drug, has since been widely used for conditions such as neuropathic pain, generalized anxiety disorder, and fibromyalgia. However, increasing concerns have emerged regarding its misuse and abuse potential, especially among opioid-dependent populations. This study aimed to perform a comprehensive bibliometric analysis to evaluate global research trends, identify prolific contributors, and explore collaborative networks related to pregabalin misuse.
Materials and Methods: A bibliometric design was employed using the Web of Science Core Collection database. The search was performed in February 2025, and publications were selected based on predefined criteria. A total of 449 eligible records were analyzed. The bibliometrix R package and its web application, Biblioshiny, within the RStudio environment, were used to conduct statistical and network analyses.
Results: Scientific publications addressing pregabalin misuse have markedly increased since 2010. The United States was the most prolific and central actor in global research collaborations, followed by the United Kingdom, Germany, and France. Prominent authors and institutions were found to form tight academic clusters. A steady rise in the usage of keywords such as “abuse,” “addiction,” and “opioids” was observed, particularly after 2016.
Conclusion: The growing literature on pregabalin misuse reflects heightened global awareness. Research remains centered in high-income countries, though emerging contributions from developing regions, including Türkiye, are notable. These findings underline the need for interdisciplinary cooperation, informed policy development, and enhanced clinical monitoring to address the risks associated with pregabalin misuse.
Ključne reči
Array
Array
Array
Array
Reference
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.